Single cell resolution in vivo imaging of DNA damage following PARP inhibition

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yang, Katherine S ^a   Kohler, Rainer H ^a   Landon, Matthieu ^a,b   Giedt, Randy ^a   Weissleder, Ralph ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; SIGNAL PEPTIDE; TP53BP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR P53 BINDING PROTEIN 1;

ANIMAL; DISEASE MODEL; DNA DAMAGE; DRUG EFFECTS; DRUG RESISTANCE; EWING SARCOMA; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; MOLECULAR IMAGING; MOUSE; MUTATION; REPORTER GENE; SINGLE CELL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENES, REPORTER; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MOLECULAR IMAGING; MUTATION; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; SARCOMA, EWING; SINGLE-CELL ANALYSIS; TUMOR SUPPRESSOR P53-BINDING PROTEIN 1;

EID: 84929624401     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10129     Document Type: Article

References (51)

1. Kameshita, I., Matsuda, Z., Taniguchi, T. & Shizuta, Y. Poly (ADP-Ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain. J Biol Chem 259, 4770-4776 (1984).
2. Jagtap, P. & Szabo, C. Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4, 421-440 (2005).
3. D'Amours, D., Desnoyers, S., D'Silva, I. & Poirier, G. G. Poly (ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 342, 249-268 (1999).
4. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10, 293-301 (2010).
5. Gibson, B. A. & Kraus, W. L. New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13, 411-424 (2012).
6. Juarez-Salinas, H., Sims, J. L. & Jacobson, M. K. Poly (ADP-ribose) levels in carcinogen-treated cells. Nature 282, 740-741 (1979).
7. Benjamin, R. C. & Gill, D. M. ADP-ribosylation in mammalian cell ghosts. Dependence of poly (ADP-ribose) synthesis on strand breakage in DNA. J Biol Chem 255, 10493-10501 (1980).
8. Durkacz, B. W., Omidiji, O., Gray, D. A. & Shall, S. (ADP-ribose) n participates in DNA excision repair. Nature 283, 593-596 (1980).
9. Gagne, J. P. et al. Proteome-wide identification of poly (ADP-ribose) binding proteins and poly (ADP-ribose)-associated protein complexes. Nucleic Acids Res 36, 6959-6976 (2008).
10. Timinszky, G. et al. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat Struct Mol Biol 16, 923-929 (2009).
11. Kraus, W. L. New functions for an ancient domain. Nat Struct Mol Biol 16, 904-907 (2009).
12. Ahel, D. et al. Poly (ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 325, 1240-1243 (2009).
13. Gottschalk, A. J. et al. Poly (ADP-ribosyl) ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc Natl Acad Sci USA 106, 13770-13774 (2009).
14. Masson, M. et al. XRCC1 is specifically associated with poly (ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18, 3563-3571 (1998).
15. El-Khamisy, S. F., Masutani, M., Suzuki, H. & Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31, 5526-5533 (2003).
16. Nobori, T., Yamanaka, H. & Carson, D. A. Poly (ADP-ribose) polymerase inhibits DNA synthesis initiation in the absence of NAD. Biochem Biophys Res Commun 163, 1113-1118 (1989).
17. Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105, 17079-17084 (2008).
18. Kortmann, U. et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 17, 783-791 (2011).
19. Drew, Y. et al. Therapeutic potential of poly (ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103, 334-346 (2011).
20. Dimitrova, N., Chen, Y. C., Spector, D. L. & De Lange, T. 53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility. Nature 456, 524-528 (2008).
21. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
22. Panier, S. & Boulton, S. J. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol 15, 7-18 (2014).
23. Pryde, F. et al. 53BP1 exchanges slowly at the sites of DNA damage and appears to require RNA for its association with chromatin. J Cell Sci 118, 2043-2055 (2005).
24. Lukas, C. et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol 13, 243-253 (2011).
25. Zgheib, O., Pataky, K., Brugger, J. & Halazonetis, T. D. An oligomerized 53BP1 tudor domain suffices for recognition of DNA double-strand breaks. Mol Cell Biol 29, 1050-1058 (2009).
26. Karanam, K., Kafri, R., Loewer, A. & Lahav, G. Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. Mol Cell 47, 320-329 (2012).
27. Orth, J. D. et al. Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. Cancer Res 71, 4608-4616 (2011).
28. Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat Commun 4, 1504 (2013).
29. Fong, P. C. et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361, 123-134 (2009).
30. O'Shaughnessy, J. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364, 205-214 (2011).
31. Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triplenegative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12, 852-861 (2011).
32. Kaye, S. B. et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30, 372-379 (2012).
33. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366, 1382-1392 (2012).
34. Liu, X. et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 18, 510-523 (2012).
35. Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G. & Kaufmann, S. H. Failure of iniparib to inhibit poly (ADP-Ribose) polymerase in vitro. Clin Cancer Res 18, 1655-1662 (2012).
36. Annunziata, C. M. & O'Shaughnessy, J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 16, 4517-4526 (2010).
37. Helleday, T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5, 387-393 (2011).
38. Mangerich, A. & Burkle, A. How to kill tumor cells with inhibitors of poly (ADP-ribosyl) ation. Int J Cancer 128, 251-265 (2011).
39. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 434, 913-917 (2005).
40. Menear, K. A. et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem 51, 6581-6591 (2008).
41. Evers, B. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14, 3916-3925 (2008).
42. Garber, K. PARP inhibitors bounce back. Nat Rev Drug Discov 12, 725-727 (2013).
43. Guha, M. PARP inhibitors stumble in breast cancer. Nat Biotechnol 29, 373-374 (2011).
44. Tulin, A. Re-evaluating PARP1 inhibitor in cancer. Nat Biotechnol 29, 1078-1079 (2011).
45. Jelinic, P. & Levine, D. A. New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair. Mol Cancer Ther 13, 1645-1654 (2014).
46. Nguyen, D. et al. Poly (ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 10, 4074-4082 (2011).
47. Kubota, E. et al. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle 13, 2129-2137 (2014).
48. Lacroix, M., Toillon, R. A. & Leclercq, G. p53 and breast cancer, an update. Endocr Relat Cancer 13, 293-325 (2006).
49. Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 14, 169-177 (2012).
50. Olivo-Marin, J.-C., Extraction of spots in biological images using multiscale products. Pattern Recognition 35, 1989-1996 (2002).
51. Starck, J.-L., Murtagh, F. & Bijaoui, A. In Image processing and data analysis: the multiscale approach 1st edn (Cambridge University Press, 1998).